Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe webpage has been updated to reflect a new phase II open-label study of nivolumab combined with ipilimumab and bicalutamide for HER2-negative metastatic or unresectable breast cancer, with changes in the study's collaborators and revision number. The previous goal of the protocol has been removed, indicating a shift in focus.SummaryDifference50%
- Check53 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, indicating a new release. Additionally, a date has been added, which may signify an important upcoming event or deadline.SummaryDifference0.2%
- Check82 days agoChange DetectedThe webpage has updated its date-related content, removing several past dates and adding new future dates, indicating a shift in the timeline of events or availability.SummaryDifference0.8%
- Check89 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.